• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012 Product Image

Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012

  • Published: January 2012
  • 28 pages
  • Global Markets Direct

Organophosphate And Carbamate Poisoning – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012', provides an overview of the Organophosphate And Carbamate Poisoning therapeutic pipeline. This report provides information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning. 'Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Organophosphate And Carbamate Poisoning Overview
Therapeutics Development
An Overview of Pipeline Products for Organophosphate And Carbamate Poisoning
Organophosphate And Carbamate Poisoning Therapeutics under Development by Companies
Organophosphate And Carbamate Poisoning Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Organophosphate And Carbamate Poisoning Therapeutics – Products under Development by Companies
Organophosphate And Carbamate Poisoning Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Organophosphate And Carbamate Poisoning Therapeutics Development
MicroDose Therapeutx, Inc.
Organophosphate And Carbamate Poisoning – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Atropine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Organophosphate And Carbamate Poisoning Therapeutics – Drug Profile Updates
Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products
Organophosphate And Carbamate Poisoning – Product Development Milestones
Featured News & Press Releases
Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning
Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day
Jun 08, 2010: Protalix Completes Phase I Clinical Trial For PRX-105
Sep 23, 2009: MicroDose Therapeutx Announces Initiation Of Phase I Study With Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Organophosphate And Carbamate Poisoning, H1 2012
Products under Development for Organophosphate And Carbamate Poisoning – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
MicroDose Therapeutx, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Organophosphate And Carbamate Poisoning Therapeutics – Drug Profile Updates
Organophosphate And Carbamate Poisoning Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Organophosphate And Carbamate Poisoning, H1 2012
Products under Development for Organophosphate And Carbamate Poisoning – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos